跳至主要内容
临床试验/NCT03802409
NCT03802409Unknown不适用

The Real Word Study of Albumin-binding Taxol for Lung Cancer Treatment

The First Affiliated Hospital of Anhui Medical University1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2019年1月20日最近更新:
适应症

试验速览

阶段
不适用
入组人数
500
试验地点
1
主要终点
Progress free survival

研究概览

简要总结

The investigators conduct the real world study to explore the efficacy and safety of Albumin-binding taxol in lung cancer .

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female patients .
  • Confirmed by Histopathology or Cytology of Lung Cancer
  • Patients should be voluntary to the trial and provide with signed informed consent
  • The researchers believe patients can benefit from the study.

排除标准

  • Patients with a known history of allergic reactions and/or hypersensitivity attributed to Albumin-binding taxol or its accessories
  • Pregnant or lactating women
  • Patients with Albumin-binding taxol contraindications
  • Patients of doctors considered unsuitable for the trial

结局指标

主要结局

Progress free survival

时间窗: 1 year

Progress free survival is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.

次要结局

  • Overall Survival(3 year)
  • Objective tumor response rate(1 year)
  • disease control rate(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验